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The Médecins Sans Frontières (MSF) ethics review board (ERB) has been solicited in an unprecedented way to
provide advice and review research protocols in an ‘emergency’ mode during the recent Ebola epidemic.
Twenty-seven Ebola-related study protocols were reviewed between March 2014 and August 2015, ranging
from epidemiological research, to behavioural research, infectivity studies and clinical trials with investigational
products at (very) early development stages. This article examines the MSF ERB’s experience addressing issues
related to both the process of review and substantive ethical issues in this context. These topics include lack of
policies regarding blood sample collection and use, and engaging communities regarding their storage and
future use; exclusion of pregnant women from clinical and vaccine trials; and the difficulty of implementing
timely and high-quality qualitative/anthropological research to consider potential upfront harms. Having
noticed different standards across ethics committees (ECs), we propose that when multiple ethics reviews of
clinical and vaccine trials are carried out during a public health emergency they should be accompanied by
transparent communication between the ECs involved. The MSF ERB experience should trigger a broader dis-
cussion on the ‘optimal’ ethics review in an emergency outbreak and what enduring structural changes are
needed to improve the ethics review process.
Introduction
The size and scale of the 2014–2015 Ebola virus disease
(EVD) epidemic in West Africa, due to the Guinean
Zaire Strain, were unprecedented. Starting in March
2014, when the Ebola virus was identified as the causa-
tive agent of a haemorrhagic fever infection in Guinea
(Baize et al., 2014; Dixon and Schafer, 2014) the
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epidemic eventually spread over several countries,
Guinea, Liberia and Sierra Leona being the most af-
fected. While Médecins Sans Frontières (MSF) has
helped to control Ebola outbreaks in nine countries
over the past 20 years, the recent epidemic that raged
in West Africa proved uniquely catastrophic. MSF’s
West Africa Ebola response started in March 2014 push-
ing it to the limits and beyond. MSF set up 15 Ebola
management and transit1 centres in the three most af-
fected countries (Marchbein, 2015). As of November
2015, a total of 10,363 Ebola-suspected patients had
been admitted to MSF treatment centres, which corres-
ponds to 36 per cent of all confirmed, probable and
suspect cases reported by World Health Organization
(WHO). In total 5226 confirmed Ebola cases were trea-
ted by MSF, a third of the confirmed cases reported by
WHO (2015).
Although Ebola outbreaks have been occurring for
almost 40 years (WHO, 1978), no specific vaccines or
curative treatments for EVD had been developed up to
2014 (Goodman, 2014). Thus, throughout (most of) the
West African epidemic, EVD treatment has primarily
been supportive, including intravenous or oral rehydra-
tion, nutrition, pain killers, treatment of co-infections
with antibacterial and antimalarial drugs and blood
transfusion when appropriate (Feldmann and
Geisbert, 2011; Chertow et al., 2014). Despite these
interventions, mortality remained high (WHO Ebola
Response Team, 2014).
The unprecedented scale of this Ebola epidemic, the
lack of effective preventive or curative interventions, the
fact that the outbreak initially seemed to be able to cross
national borders and reach high-income countries,
combined with mathematical models predicting contin-
ued explosive growth led to an equally unprecedented,
although delayed and initially slow-paced, response
(Lancet editorial, 2014; Gulland, 2015) to develop and
test new treatments and vaccines to prevent and control
the further spread of the epidemic. WHO held a series of
relevant meetings in August and September 2014. The
Emergency Committee invoked the International
Health Regulations to declare the EVD outbreak a
public health emergency of international concern.
Shortly thereafter, an ethics panel convened by WHO
unanimously declared that it was ethically permissible to
use unregistered interventions (including those not pre-
viously used or tested in humans) in the treatment of
Ebola patients assuming that certain conditions were
met. Subsequent meetings elaborated principles related
to ethics and clinical trials (WHO, 2014a, b, c). Soon
after the WHO panel, MSF convened an internal meet-
ing where reluctance concerning clinical trials was
voiced, since these require significant resources for com-
plying with Good Clinical Practices and regulatory re-
quirements, thus diverting attention and energy away
from patients in very resource-limited settings. The ap-
propriateness of ‘compassionate use’ in this context was
also discussed.
Given that MSF was providing care to Ebola patients
since the start of the epidemic, has considerable experi-
ence in managing Ebola treatment centres and was at-
tending an important proportion of suspected and
confirmed Ebola cases in the three most affected coun-
tries, the organization was immediately contacted by
many commercial and non-commercial research
groups interested in testing preventive and therapeutic
tools to fight EVD. MSF itself as a medical humanitarian
organization felt a moral duty to carry out research to
improve its interventions in several aspects, despite
some initial reluctance, expressed at the meeting noted
above. In addition, the question of ‘compassionate use’,
later reworded into ‘monitored emergency use’ of
experimental drugs and vaccine2 appeared early on in
the epidemic, and some humanitarian workers evacu-
ated to their countries of origin received experimental
interventions. The issue of ‘monitored emergency use’
was felt as very relevant at MSF. After initial general joint
reflection among MSF medical directors and the MSF
ethics review board (ERB), these programs were sub-
mitted for ethical review, aiming at ensuring the best
possible protection of subjects and the best possible
knowledge gain.
Since the beginning of 2014, the MSF ERB has been
solicited in an exceptional way to provide advice and
review research protocols in an ‘emergency’ mode. This
article examines the MSF ERB experience in reviewing
the research MSF has carried out, either as the coordi-
nating or as a partner institution, during the West
African Ebola epidemic. The functioning of the MSF
ERB has been described in two previous articles and
will not be further discussed here (Schopper et al.,
2009, 2015). We will describe MSF ERB activity, address
issues related to the review process itself and analyse
substantive ethical issues raised by EVD research (pro-
posed or conducted). Particular focus will be placed on
how the ERB responded to a surge in protocols under
tight timelines and the problems raised by simultaneous
reviews by multiple committees. Key substantive ethical
issues include collection, storage and future use of blood
samples; exclusion of pregnant women; and poorly de-
signed anthropological research. Some of these present
such a high degree of complexity that they deserve fur-
ther analysis elsewhere.
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Thankfully, the devastating West African Ebola emer-
gency appears to be at an end, leading to a time for
reflection on necessary reforms before the next pan-
demic (Moon et al., 2015). We hope that the MSF
ERB experience may trigger a broader discussion of ‘op-
timal’ procedures for ethics review in an emergency out-
break and enduring structural changes needed to
improve ethics review processes in such complex, extra-
ordinary, high-stake settings.
Procedural Issues Faced by the
MSF ERB during the West African
EVD Epidemic
Range of Protocols Reviewed and MSF ERB
Workload
The MSF ERB reviewed 27 Ebola-related study protocols
between March 2014 and August 2015 (Table 1).
Research protocols reviewed covered a variety of different
types of study, including epidemiological research, be-
havioural research, infectivity studies3 and clinical trials
with investigational products at (very) early development
stages. Some other elements added to the complexity of
the ethics review process are as follows: research was done
during an epidemic, involving highly vulnerable popula-
tions faced with a deadly disease; research activities
spanned over three low-income countries, with fragile
health systems, poor infrastructure and little experience
of medical research (and in particular for clinical trials);
some research was carried out in collaboration with aca-
demic institutions, which required setting up new collab-
orative research agreements very quickly; and clinical
trials with investigational products were sponsored by
not-for-profit organizations other than MSF and/or by
pharmaceutical companies. For drug and vaccine trials,
the pharmaceutical companies played a key role even if
they were not the legal sponsor of the trial, since they
provided the investigational product. For example, in
one trial which investigated the efficiency of a new
drug, the legal sponsor (a University) could not oppose
the company’s decision to withdraw the drug soon after
inclusion of the first patients. The studies reviewed by the
MSF ERB were all carried out inside MSF sites and with
few exceptions directly involved patients or health staff at
MSF Ebola Treatment Centres (ETCs).
As shown in Figure 1 Ebola-related protocols added
substantially to the MSF ERB’s workload particularly in
2015. In the first semester of 2015, 17 new protocols
were submitted while the epidemic was declining.
The workload did not only increase due to the num-
bers of protocols, but also because a higher proportion of
the protocols than usual needed full review which implies
involvement of all MSF ERB members (Schopper et al.,
2009). Usually less than 10 per cent of protocols sub-
mitted to the MSF ERB are submitted to full review. As
shown in Figure 2 in the case of Ebola-related research,
overall 40 per cent of the protocols required full review,
and up to half of them in 2014 including most of the
clinical trials. The combination of increased workload
and unpredictability of the timing of new submissions
created difficulties for individual members given other
work and personal commitments.
With the exception of four protocols, all studies were
submitted for MSF ERB review after a 2-day meeting,
held in mid-October 2014, and attended by all MSF ERB
members, MSF medical directors and relevant researchers.
The exchanges at that meeting provided mutual under-
standing of the upcoming ethical challenges and a consen-
sus as to how they could be addressed. For example, detailed
discussions were held about trial methodology, and a con-
sensus developed to use historical controls rather than ran-
domization between treatment options or placebos. This
discussion was heavily influenced by the need to remain
true to MSF’s humanitarian mission and an ethical concern
to ensure that no potential participants were disadvantaged
in terms of a chance to receive a potentially life-saving inter-
vention in a situation with such high mortality rates. This
very usefully informed the review process without affecting
the independence of the MSF ERB judgements. It was es-
sential in ensuring the rapid turnaround and a constructive
debate before, during and after ethics review.
Timeliness and Consistency of MSF ERB Review
The MSF ERB responded promptly to the initial request
as well as the responses of the investigators. On average
it took 12.4 days to provide a review after the initial re-
quest. Thereafter, the MSF ERB responded within 1–4
days to the replies of the investigators. This was particu-
larly remarkable for the clinical and vaccine trials mean-
ing complex protocols with unknown risk of potential
harm, thus needing full review and particularly stringent
scrutiny. Figures 3 and 4 illustrate this with the timeline
for two complex clinical protocols.
The average time from request to approval of the five
clinical research protocols by the MSF ERB was 35 days,
ranging from 23 to 43 days. MSF ERB follow-up after ini-
tial approval of each protocol included further formal ap-
proval of one or several amendments, assessment of
interim reports and assessing the potential impact of the
research.
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As the MSF ERB reviewed many Ebola-related proto-
cols almost simultaneously, it was important for us to
ensure similar standards, in particular across the clinical
trials and the protocols for monitored emergency use of
unregistered interventions (MEUURI), a term adopted
by the WHO Ebola Ethics Working Group to replace
the expression ‘compassionate use’. Major ethical
issues, such as storage and future use of blood/plasma
samples, post-trial access, consent of highly vulnerable
patients, inclusion of pregnant women were identified
across trials. Although the design was different, many
ethical issues raised by the vaccine trial were compar-
able. Some of these will be briefly discussed later in this
article.
How to Deal with Multiple Review Processes
Most Ebola research protocols reviewed by the MSF
ERB during the West African EVD were also reviewed
by other institutional review boards (IRBs) and research
ethics committees (ECs) in the countries where studies
were undertaken and at key research partner institu-
tions. These included: the University of Liberia, Pacific
Institute for Research and Evaluation, Institutional
Research Board; Comité National d’Ethique pour la
Recherche en Santé de Guinée; the WHO Ethical
Review Committee; the ECs of the Oxford University
and of the London School of Hygiene and Tropical
Medicine in the UK; the IRB of the Institute of
Tropical Medicine; the Ethics Evaluation Committee
Table 1. Ebola-related study protocols reviewed by the MSF ERB between March 2014 and August 2015
Type of research Number of protocols MSF’s relationship with the proposed
research






3 MSF not the legal sponsor; in part-
nership with academic institutions
Vaccine trial (Part A: ring vaccin-
ation; Part B: vaccination of
front line workers)/
PACTR201503001057193
Two distinct protocols for
two substudies (Parts A and B)
WHO was the sponsor, but MSF
took responsibility for implement-
ing Part B, as this was carried out
on frontline workers employed and




9 Seven MSF sponsored, including one
generic protocola
Two developed and sponsored by
academic institutions as companion
research to clinical trials
Infectivity studies (one on pa-
tients; one on environmental
samples)
2 MSF sponsored












aGeneric protocol: A protocol submitted for ERB review and approval before the exact location of the disaster is known. This
procedure was adopted by the MSF ERB to facilitate research in disaster situations. Once the disaster happens and location is
known, the details can be filled in and subjected to expedited review to allow the protocol to be applied in a specific setting.
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Figure 1. MSF ERB workload before and during the Ebola epidemic.
Includes only protocols submitted by August 2015.
Figure 2. Type of review for Ebola protocols.
The vaccine trial is counted as two protocols: Parts A and B.
Figure 3. Timeline of review process for RAPIDE Trial (Brincidofivir, Liberia).
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of INSERM (the French National Institute of Health and
Medical Research); and the Ethics Committee of the
Antwerp University Hospital in Belgium. Of the 27
protocols reviewed by the MSF ERB, 11 were in add-
ition reviewed by a national EC only, while 7 were re-
viewed by a national EC and one or several ECs/IRBs
from other international institutions or academic cen-
tres. While it is the rule of the MSF ERB that all proto-
cols must also be submitted to the relevant national EC,
in eight instances this was not the case. As pre- and post-
exposure prophylaxis could initially only be provided
outside of the affected country, these protocols did
not receive local approval, but underwent ethical scru-
tiny in the country where prophylactic treatment was
going to be provided. Furthermore, two protocols were
exempted from review; in two instances advice only was
provided on MEUURI: one generic protocol was pre-
approved and only later submitted to the national
EC and one low-risk qualitative study was carried out
in the UK.
Double ethics review, in the study country(ies) and in
the country of the sponsor, has been recommended for
ensuring protection of subjects and their communities
in medical research sponsored, coordinated or funded
by foreign organizations in low and middle income
countries (Ravinetto et al., 2011). But it also raises im-
portant regulatory and feasibility issues, e.g. it is recom-
mended, but generally not mandatory—with the
notable exception of a few African regulators (Ethiopia
Ministry of Science and Technology, 2014; Uganda
National Council for Science and Technology, 2014),
and its usefulness may be limited if the different IRBs/
ECs cannot have access to each other’s reviews (in prac-
tice, often only researchers have access to the different
reviews). During the West African EVD epidemic, one
study group positively evaluated the receipt of multiple
ethics reviews, noting that the complementarity of the
reviews raised the quality of the research and the pro-
tection of participants and community (De Crop et al.,
2016), but they also argued that more should be done to
harmonize the multiple review process in ‘urgency’ situ-
ations, by fostering direct dialogue among ECs. This is
in line with the recommendation of the WHO’s 2009
report on Research Ethics in International Epidemic
Response (‘it is crucial to streamline the ethics review
process and to establish appropriate, flexible mechan-
isms and procedures for ethical oversight not limited to
traditional REC systems’) (WHO, 2009), and with the
more recent WHO Background Document on Potential
Ebola Therapies and Vaccines (WHO, 2014b), which
stated that ‘flexible approaches are required to harmon-
ize various review processes, and ensure that the various
ECs can review the projects simultaneously and share
and discuss the review outcomes with each other’.
Unfortunately, during this EVD epidemic no coordin-
ation mechanisms were set to implement such a ‘simul-
taneous ethical review’. This may be due to a mix of
different reasons, e.g. there was no time to be spent in
organizing meetings and teleconferences; there was no
specific funding for supporting physical meetings (up to
six bodies were involved in the review of a same proto-
col, and it is not clear who would be responsible to fund
the meetings); and the availability of new technologies
for audio- and videoconferences has been seriously
underused. In some cases the MSF ERB (as well as, pre-
sumably, the other concerned IRB/ECs) was initially not
even informed about which other ethical review boards
or committees were going to assess a same protocol.
The lack of joint ethical review for Ebola clinical trials,
or at least of proactive communication among ECs re-
viewing the same Ebola trial protocol(s), may have been
a missed opportunity to streamline the different reviews
Figure 4. Timeline of review process for Jiki Trial (Favipiravir, Guinea).
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into a comprehensive review (potentially, an advantage
for the researchers) and to foster dialogue and mutual
learning among the different ECs/IRBs (potentially, an
advantage for the ECs/IRBs). Even if it ensured inde-
pendence of judgment, the fact that the different ECs/
IRBs were ‘blinded’ to each other’s reviews prevented
the exchange of views, shared approaches to new di-
lemmas and agreement on common review policies
(e.g. the MSF ERB possibility to pre-review generic
protocols for research in emergency (Schopper et al.,
2015) could be interesting also for other EC/IRBs).
Also, the lack of mutual knowledge and communication
may have potentially weakened the impact of the ethics
review. The striking differences in issues raised by ECs in
certain instances may have been difficult to reconcile for
the researchers (De Crop M et al., 2016). Also, research
groups might ‘shop around’ ECs, and use one favour-
able opinion from a less stringent body to influence
other ECs to agree on it.
These difficulties, even if exacerbated by the context
of a public health emergency, are not unique to Ebola
research. While double or multiple reviews of interna-
tional research protocols are common, we are not aware
of any successful mechanisms for joint ethics review
(Meslin et al., 2014; Tierney et al., 2013), with a single
reported exception from the field of human African
trypanosomiasis. A ‘pre-review’ process of the protocols
for DNDi and partners’ pivotal Phase II/III fexinidazole
study brought together in 2012 the Ethics unit of WHO
and representatives of ECs from six African countries,
with the aim of reducing duplication of efforts
(Coleman et al., 2015). This model of joint ‘pre-review’
of the ethical challenges foreseeable within a whole re-
search plan, may be feasible for a public health emer-
gency, if representatives of relevant organizations are
pre-identified, available to meet on short notice, the
resultant consensus review is agreed in advance to be
acceptable to all and some organization takes on the
role of coordination and engagement with the
researchers.
Substantive Ethical Issues of
Concern
The fact that research was done during an epidemic,
involving highly vulnerable populations faced with a
deadly disease, and that research activities spanned
over three low-income countries, with poor health in-
frastructure and governance—where trust in the health-
care system and/or international healthcare providers
was revealed to already be lacking—implied in our
view, the need for especially careful and stringent
ethics review. The question of the trial designs to be
chosen that dominated the ethical debate in 2014 had
been resolved upfront in discussions with MSF based on
the WHO consultation (WHO, 2014c). Some of the
issues the MSF ERB consistently raised in its reviews
were how to obtain truly informed consent of patients
facing a high chance of death in a high-safety
environment, the high potential for therapeutic or phil-
anthropic misconception,4 as MSF was the only
healthcare provider for Ebola patients in many instances
(Ahmad and Mahmud, 2010) and community engage-
ment. In addition, two questions were particularly dif-
ficult to address in a satisfactory manner: the storage of
blood samples for future use and the exclusion of preg-
nant women in clinical trials.
Blood Samples: Collection, Storage, Future
Twelve of the 27 protocols reviewed involved the collec-
tion of blood samples as one of the inclusion criteria and
as part of efficacy/safety assessment in the trial. The MSF
ERB policy (Schopper et al., 2009) requires investigators
to clearly indicate if blood samples will be destroyed
after use in the study and, if not, that ECs and patients
be informed about storage and potential future use of
the samples. In case of potential future use, our policy
requires that the patient be explicitly informed about the
conditions for future use, such as not using the sample
for any commercial purposes, and a statement that sam-
ples will only be used in any future research after ethics
approval and that results will be made available to all
those in need by using all possible ‘access mechanisms’.
We also require that patients be given the option of
declining future use. It became clear that the views on
this matter were strikingly different between ECs. Given
the low to non-existent capacity for safe storage and
analysis of the samples in the three countries concerned,
samples were exported to other countries. The MSF ERB
insisted on proper Material Transfer Agreements as is
standard international practice.5
In addition, we insisted on the urgent need to develop
policies regarding sample collection and use and engage
communities regarding their storage and future use.
This does not only apply to blood collected during re-
search with explicit consent, but more generally to bio-
logical specimens collected while providing clinical care
over the duration of the outbreak. It is estimated that
overall about 80,000 specimens now exist in the after-
math of the epidemic. Their precise location is unre-
ported (Marchbein, 2015). There are plans to create a
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biobank to drive research and development for diagnos-
tics, vaccines and therapeutics, as well as for further
understanding the molecular and virological character-
istics of Ebola virus. The nature of this biobank, where it
will be located, how it will be governed, who will have
access, all remain unclear.
It is important to note that no explicit informed con-
sent was received for the use of the clinically collected
specimens for the purpose of future research. It might be
argued that consent is no longer feasible and failure to
use these specimens to advance scientific knowledge
would be unethical. While it may be tenable to claim
that the urgency of a response trumped the necessity for
appropriate collection of samples and that consent was
not feasible in the context of the outbreak, given well-
documented concerns around biopiracy and exploit-
ation in the context of colonial past, it is a moral failure
not to have considered how this issue may be addressed
in other ways. Given the special value commonly placed
on blood in West African countries, adverse implica-
tions regarding local communities’ trust in healthcare
systems and/or international healthcare providers
should not be underestimated. There clearly needs to
be an agreed upon process as to how the samples are
stored and anonymized, how researchers access the sam-
ples and who has the authority to permit access and use.
Proactive strategies to encourage scientific capacity in
the affected nations could be an enduring positive legacy
from the outbreak.
Excluding Pregnant Women
Pregnant women infected with Ebola were excluded
from two of the clinical trial proposals and the vaccine
trial reviewed by the MSF ERB, despite evidence of
higher than average fatality rates during pregnancy
(Baggi et al., 2014) and extremely poor survival rates
of the foetus. Among the clinical trials with therapeutic
agents, only the convalescent plasma studies did not
stipulate pregnancy as an exclusion criterion. In our
view there was no strong justification for excluding
pregnant women from the Ebola clinical trials. The
reason usually cited for excluding pregnant women
was possible embryotoxicity. Most made this prediction
based on data from animal models. However, across
Ebola outbreaks since 1995 there is a reported 100 per
cent fatality rate for foetuses of infected women
(Kitching et al., 2015). Only recently has one baby sur-
vived after delivery in an ETC,6 and she was given in-
vestigational treatments from birth. Her mother sadly
died from the Ebola infection. In addition, data col-
lected during an outbreak in 1996 in the Democratic
Republic of the Congo indicate that pregnant women
are more likely to have haemorrhagic complications
associated with delivery or termination, including vagi-
nal and uterine bleeding (Jamieson et al., 2014). Because
of the context and known outcomes of Ebola on preg-
nancies, we found prioritizing concerns about potential
foetal harm to be inappropriate and so focused on how
to better evaluate the risks and potential benefits of trial
participation by women during pregnancy. There was
no evidence that the investigational agents would cause
specific risks to the women’s health in pregnancy, and
the evidence indicates extremely low chance of in utero
survival. As a result, we chose to explore how the
women’s interests could be fairly respected, and whether
the exclusion criteria were justifiable. Our conclusion,
based on the information above, was that their exclusion
promoted unfair access to any potential benefits of en-
rolment in these trials, so we chose instead to emphasize
inclusion of pregnant women with appropriate in-
formed consent.
Special consideration of pregnant women is a univer-
sally accepted norm in research ethics guidance, but
recent refinements in its application emphasize that ex-
clusion should not be applied without strong justifica-
tion (Baylis and Halperin, 2012; Foulkes et al., 2011;
Lyerly et al., 2008). It is increasingly recognized that
wholesale exclusion of pregnant women from clinical
trials unjustly denies them access to the benefits of par-
ticipating in research, and makes them more vulnerable
to potentially unsafe practices such as informal off-label
use of medications or unguided use in special access
programs which normally do not have formal oversight.
The CIOMS Guideline 15 and 197 reflect this discourse
in bioethics which is increasingly advocating for re-
searchers to provide justifications for exclusion rather
than inclusion as has been the tradition so far. While we
accept there is no individual right to access to research
interventions, we argue there is a right not to be
excluded from research for unreasonable factors. Thus
we considered the following to help evaluate risks and
benefits for pregnant women in clinical trials for Ebola,
and would use these in other contexts as well. The pri-
mary question was: Is the exclusion of pregnant women
justified in this study? This was examined on the follow-
ing considerations: What are the clinical outcomes for
pregnancies in this context? What is the average time
from infection/diagnosis to mortality? Is it altered
during pregnancy? Do the criteria for exclusion include
a balance of risks and benefits for both the foetus and the
mother? What phase is the study? Are there any existing
safety data for the intervention? What other inter-
ventions are available? Whose interests should be
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considered in our determination? As new disease out-
breaks emerge, such as Zika virus, it is less and less likely
that excluding pregnant women from research will be
feasible. With proper study design and proper research
oversight risks in research can be mitigated or justified
for any vulnerable population—including pregnant
women.
In the interests of timely review, we did not refuse to
approve the protocols that excluded pregnant women.
We did however stress our concern and MSF responded
where it could by implementing MEUURI programmes
so pregnant women could obtain experimental treat-
ments that were unavailable for them in trials. As it
turned out, these were not drugs undergoing ‘First in
Human’ trials, which it had been anticipated would be
the only option, but new (‘off-label’) use of existing
treatments already used for care of pregnant women
with other infections or in the case of blood plasma
transfusions which pregnant women are not usually
excluded from (Kombe et al., 2016). We saw this as a
tolerable compromise. We emphasized the importance
of proper oversight and data collection on the treatment
and outcomes for these patients, because even incre-
mental knowledge of this sort can contribute to improv-
ing outcomes for pregnant women in future outbreaks.
Interestingly, only one national EC and one further EC
of an international organization took a similar stand on
this issue.
Qualitative Research
In total, the MSF ERB received nine qualitative studies
for review. The issues addressed in the protocols ranged
from program assessment to knowledge, attitudes, per-
ceptions and practices related to acceptability, suitabil-
ity and barriers to Ebola trials and interventions.
EVD being a highly infectious disease with rapid pro-
gression and high fatality rate, it is critical to understand
the knowledge, attitudes, beliefs and practices of the
community of research to adapt the response. In West
Africa, low levels of formal education, religious notori-
ety, deep-seated cultural beliefs and values, suspicion
and mistrust of government and international agencies
must be taken into consideration in control efforts and
when implementing clinical and vaccine trials (Gidado
et al., 2015; Abramowitz et al., 2015; Peters, 2014). For
example, to limit further spread of the disease, MSF and
other agencies initially isolated and quickly disposed of
the bodies of those who died to avoid further infections.
But this disappearance of friends and relatives when they
were taken to a treatment unit raised suspicions and
fears (Omidian and Monger, 2014).
In reviewing qualitative research protocols, the MSF
ERB noted that implementing timely qualitative re-
search, safeguarding ethical standards, seemed problem-
atic because:
 Lines between what constitutes qualitative data col-
lection for programmatic purposes (often labelled
rapid assessment) and actual research are blurred;
 Qualitative studies are considered to be low risk be-
cause no physical interventions or biological mater-
ials are introduced or extracted from study
participants, and thus less importance may be given
to sound study design and ethical issues which can
arise in the conduct of qualitative studies. Such an
approach can underestimate the potential harms that
can affect respondents and communities that take
part in qualitative studies (Townsend et al., 2010);
 Most ECs/IRBs are not equipped to examine such
research protocols as they have limited experience
reviewing them, little social science and anthropolo-
gical expertise, and because of the ‘low risk’ percep-
tion they tend not to seek external advice (Molyneux
et al., 2009).
Among the nine, seven qualitative studies were expli-
citly designed to improve the programmatic response,
while two studies were meant to inform and accompany
clinical trials. In some cases, the research questions and
methodologies were not well laid out (which is not un-
expected in this context) and may have had potential of
generating unreliable and invalid results. This would not
only be a waste of resources, but present the potential
danger of eroding trust in science. In addition, qualita-
tive studies may pose serious and often underestimated
risks, such as confidentiality breaches during or after
focus group discussions, social stigma and psychological
harms (Oakes, 2002). The MSF ERB thus insisted that
qualitative study designs require meticulous planning
and intensive engagement with the community of re-
search, and need to carefully weigh benefits and risks.
Two studies were cancelled after our initial ethics review
raised such concerns.
Researchers should not be left alone to address the
challenges which appear in Ebola-like contexts. The
challenge of time pressure in emergency settings
should, in particular, be countered by funding agencies
that should make resources available for sound qualita-
tive research at the same time as for clinical trials; and by
ECs, that may accept the development of generic quali-
tative protocols that could be quickly and immediately
adapted and implemented in the case of an emergency
outbreak.
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Lessons Learned from the MSF
ERB Experience
A paper published in 2009 discussed the ethical chal-
lenges of research on Ebola and Marburg haemorrhagic
fevers (Calain et al., 2009). The lack of ethical oversight,
challenges to obtaining voluntary informed consent,
issues raised by collection of blood samples and future
use without consent, the need to design generic research
protocols and standards prior to emergencies and the
establishment or strengthening of national and inde-
pendent ethics research committees were highlighted.
So what have we additionally learned from the West
African EVD epidemic?
One of the remarkable features of this Ebola epidemic
has certainly been the great effort to rapidly set up clin-
ical and vaccine trials, including ethics assessments. The
ethics panel convened by WHO recommended proceed-
ing to do research on 11 August, and the first patients
were enrolled in late December 2014. This is a remark-
ably quick turnaround, given that funding mechanisms,
research partnerships, protocols, drug procurement and
clinical sites set-up, all started from scratch. Ethics
review of the trials was all the more important, as this
was emergency research carried out in an extremely vul-
nerable population faced with a deadly disease. In our
experience, it is possible to provide relevant and very
timely ethical advice even for complex protocols. We
strictly applied the usual ethical standards, as defined
in the MSF ERB framework (Schopper et al., 2015),
reinforcing them as needed. In our view ethics corner-
cutting is neither justified nor necessary even in an
emergency. This however implied a very considerable
effort on the part of the MSF ERB which could not
possibly have been sustained for an extended period of
time. In the future the substantially increased workload
of ECs should be taken into consideration in advanced
planning of emergency research.
In our view the multiple ethics reviews of clinical and
vaccine trials carried out during a public health
emergency should be accompanied by transparent com-
munication between ECs reviewing a given protocol. In
some cases, the MSF ERB (as well as, presumably, the
other concerned IRB/ECs) was initially not even in-
formed about which other ethical bodies were going to
assess each protocol. To be feasible and efficient, com-
munication mechanisms should be planned well before
the emergence of the next outbreak. Joint pre-review or
review mechanisms would be beneficial, and they could
become feasible via upfront planning and a better
use of communication technologies for audio- and
videoconferences, which have been seriously underused.
In addition, a ‘generic pre-review meeting’ could be
organized, where at the start of an outbreak representa-
tives of the ECs/IRBs who will be likely to review the
clinical trials protocols could come together to discuss
general issues and approaches to foreseeable ethical di-
lemmas (along the lines of the joint meeting of the MSF
REB and MSF Medical Directors). This raises the issue
of funding such meetings. To ease communication be-
tween ethics bodies, WHO could possibly sponsor an
EC register for such purposes akin to a clinical trial
register.
As qualitative and anthropological research is essen-
tial to improve the response and to prepare and accom-
pany clinical trials, more attention must be given to the
soundness of research protocols and ethical oversight.
Generic protocols should be prepared well in advance,
so that they can be rapidly approved for a specific set-
ting; unanticipated projects should be developed as
carefully and fully as clinical trial protocols; risks
should not be underestimated; qualitative researchers
such as anthropologists and sociologists should be
engaged early on in the development of clinical trials;
and social science expertise should be included in all
ECs.
The MSF ERB has consistently highlighted two major
ethical issues. (i) Pregnant women should obtain access
to experimental treatments either in clinical trials, or
through MEUURI. (ii) The management of bio-samples
is an integral element of protocol review (Schopper et
al., 2009). In future outbreaks, the possibility for col-
lecting and storing specimens should be anticipated,
and an explicit process should be developed to ensure
the interests of patients and communities are protected,
including proper informed consent and strategies for
community engagement.
The big irony is that despite the rapidity with which
all research was executed, the epidemic was very rapidly
waning by the time the studies were initiated. Besides
encouraging results from one vaccine trial, there are no
significant therapeutic advances yet, although ZMapp
may hold some promise (NIH, 2016). We thus know
that the research effort will have to be faster and as in-
tensive in the next epidemic. This is clearly highlighted
in the recent paper on 10 essential reforms before the
next pandemic (Moon et al. 2015), calling for appropri-
ate conduct of research including improved ethical
standards. However, the issue of ethical standards and
oversight of Ebola protocols has been surprisingly
underrepresented in the vast number of Ebola publica-
tions in 2014–2015. We hope that this article could lead
to a discussion on the ‘optimal’ way for ethics review in
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an emergency outbreak and what enduring structural
changes are needed to improve the ethics review process
in response to emergencies such as infectious disease
outbreaks.
Notes
1. Transit centres are short-stay centres for people to
await blood test results. If the test comes back nega-
tive, they will be discharged. If positive, they will be
transferred to an Ebola management centre.
2. The switch from the language of ‘compassionate
use’ to the expression MEUURI, adopted by the
WHO Ebola Ethics Working Group (see: http://
www.who.int/csr/resources/publications/ebola/eth-
ical-evd-therapeutics/en/, accessed: August 2016),
was partly motivated by concern that (i) the lan-
guage of ‘compassionate use’ seems to imply that
it would be beneficial to receive the intervention in
question (which may not be appropriate in the case
of interventions which have not previously been
tested in humans), and (ii) because ‘compassionate
use’ is often technically defined as use of an (un-
registered) intervention when use within a clinical
trial is not possible (whereas a key question regard-
ing the potential Ebola interventions in question was
whether or not their use should actually be part of a
clinical trial, which was a live possibility). The use of
‘monitored’ emphasises a key point of the WHO
Ethics Panel, i.e. that we should aim to learn as
much as possible from the use in question (i.e. by
collecting data) whether a formal clinical trial is con-
ducted (whereas ‘compassionate use’ does not
imply/highlight a data collection imperative).
3. The infectivity studies examined the infection
hazard for Ebola virus in body fluids of patients
and in environmental samples.
4. Philanthropic misconception is comparable to
therapeutic misconception. It is likely to exist
among beneficiaries of humanitarian aid when
these agencies sponsor or conduct research projects.
The participants may believe that the aim of such
researchers is primarily human welfare and the best
interests of the individuals, instead of research.
5. This ensures that the person, whom biological sam-
ples belong to, sometimes referred to as the ‘owner’,
sets the terms and conditions for the use those sam-
ples through informed consent. The institution/re-
searcher that takes the samples then becomes the
‘custodian’ of the samples and agrees to their use
as outlined by the consent. If the custodian has to
send the samples to another party (if allowed by the
consent) then it is custodian’s responsibility to make
sure by having a material transfer agreement that use
of these samples by the next party that will become
the ‘possessor’ still remains confined to the bound-
aries of the consent under which it was taken.
6. The first newborn ever surviving Ebola was reported
on 3 December 2015 by MSF https://msf.exposure.
co/nubia [accessed: August 2016].
7. CIOMS Revision of the 2002 International Ethical
Guidelines for Biomedical Research Involving
Human Subjects draft 2015, available at: http://
www.encepp.eu/documents/e-
mailgroupsCIOMSdraft30sept2015_gsf.pdf [ac-
cessed: 07 October 2015].
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